From December 10 – 14, 2013 the 36th San Antonio Breast Cancer Symposium or SABCS 2013 took place in San Antonio, Texas. In four news programs Geoff Watts interviews several invited guests to discuss the latest results of studies in the field of breast cancer and how this impact every day clinical practice. A preview of the San Antonio Meeting was published on December 9, 2013. [1]
Interviews with both lead investigators of important trials as well as young talented researchers are included as part of the daily news programs.
The guests include Professor Edith A. Perez, MD (Mayo Clinic Cancer Center, Jackdonville, FL, USA), Professor Lisa A. Carey MD (UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA), Professor Daniel F. Hayes, MD (Stuart B. Padnos Professor of Breast Cancer Research and the Clinical Director of the Breast Oncology Program in the University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA), Professor Charles Perou, Ph.D (May Goldman Shaw Distinguished Professor of Molecular Oncology Research Professor of Genetics & Pathology at the UNC Lineberger Comprehensive Cancer Center University of North Carolina, Chapel Hill, NC, USA), Seema A. Khan, MD (Bluhm Family Professor of Cancer Research, Professor in Surgery-Breast Surgery) and Professor Clifford A. Hudis MD ( Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA).
The topics being discussed include dual anti-HER2 targeting in the neoadjuvant setting, resection of the primary tumor in metastatic breast cancer, the role of ESR1 mutations in endocrine resistance, the prognosis of small HER2 tumors, new data for strategies in triple negative breast cancer and many other highlights from SABCS 2013.
Highlights from Day 1
In this program:
Geoff Watts discusses the latest news on breast cancer research with Seema A. Khan, MD. Topics discussed include:
- Whole breast irradiation in the elderly;
- The role of extracellular matrix stiffness in breast cancer;
- The first prospective results of surgery in metastatic breast cancer patients.
Highlights from Day 2
In this episode:
Geoff Watts and his guests, Professor Edith Perez, MD and Professor Lisa Carey MD, are discussing what the second day of SABCS has contributed to the treatment of breast cancer. Today’s topics Include:
- TILs (tumor infiltrating lymphocytes);
- The first survival data of dual HER2 targeting in HER2-positive early breast cancer (neo-ALLTO study).
Highlights from Day 3
In this program:
Geoff Watts and his guest, Professor Daniel Hayes, MD, are discussing new data presented at SABCS 2013. Topics in this episode include:
- Prevention of breast cancer with aromatase inhibitor anastrazole;
- Adherence and tolerability of aromatase inhibitors;
- Mutations in the estrogen receptor encoding gene and its role in endocrine resistance.
Highlights from Day 4
In this program:
Geoff Watts and his guest, Professor Charles Perou, Ph.D and Professor Clifford A. Hudis MD, are discussing new data presented at SABCS 2013, including:
- Important new data on treatment options for triple negative breast cancer;
- A meta-analysis of small HER2 positive tumors;
- The impact of genomics on breast cancer research and therapy.
For more information:
[1] A Preview of SABCS 2013 ?What?s Hot? [Article]
[2] Event-free and Overall Survival Results From NeoALTTO Trial vital for HER2+ Drug Development [Article]
[3] Trastuzumab, Docetaxel and Carboplatin Therapy Highly Effective as Adjuvant Treatment Option for Patients With HER2-positive Breast Cancer [Article]
These interviews were produced in collaboration with
 |  |
Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
